| 3.59 0.07 (1.99%) | 04-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.4  |
1-year : | 4.89 |
| Resists | First : | 3.77 |
Second : | 4.19 |
| Pivot price | 3.49 |
|||
| Supports | First : | 3.09 | Second : | 2.57 |
| MAs | MA(5) : | 3.42  |
MA(20) : | 3.56 |
| MA(100) : | 3.63 |
MA(250) : | 2.6 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 43.6 |
D(3) : | 34.2 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 5.05 | Low : | 1.21 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EDAP ] has closed below upper band by 34.7%. Bollinger Bands are 34.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.7 - 3.71 | 3.71 - 3.73 |
| Low: | 3.46 - 3.48 | 3.48 - 3.49 |
| Close: | 3.56 - 3.59 | 3.59 - 3.61 |
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
Thu, 16 Apr 2026
EDAP schedules May 7 earnings call before Q1 2026 release - Stock Titan
Thu, 16 Apr 2026
EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 - GlobeNewswire
Mon, 13 Apr 2026
HC Wainwright Has Positive Outlook for Edap Tms Q1 Earnings - MarketBeat
Sun, 12 Apr 2026
EDAP TMS Earnings Call Highlights HIFU Growth Momentum - TipRanks
Fri, 10 Apr 2026
H.C. Wainwright cuts EDAP TMS stock price target on margin headwinds - Investing.com
Wed, 01 Apr 2026
[EFFECT] EDAP TMS SA SEC Filing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 37 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 39.1 (%) |
| Shares Short | 46 (K) |
| Shares Short P.Month | 90 (K) |
| EPS | -0.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.5 |
| Profit Margin | -41.5 % |
| Operating Margin | -27.3 % |
| Return on Assets (ttm) | -17.9 % |
| Return on Equity (ttm) | -90.2 % |
| Qtrly Rev. Growth | -6.9 % |
| Gross Profit (p.s.) | 0.71 |
| Sales Per Share | 1.66 |
| EBITDA (p.s.) | -0.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -4.61 |
| PEG Ratio | 0 |
| Price to Book value | 7.03 |
| Price to Sales | 2.15 |
| Price to Cash Flow | -9.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|